{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T14:21:49Z","timestamp":1769005309095,"version":"3.49.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T00:00:00Z","timestamp":1563926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1007\/s12032-019-1298-5","type":"journal-article","created":{"date-parts":[[2019,7,24]],"date-time":"2019-07-24T10:59:40Z","timestamp":1563965980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy"],"prefix":"10.1007","volume":"36","author":[{"given":"Kazuya","family":"Kurihara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9176-1988","authenticated-orcid":false,"given":"Noriyoshi","family":"Iriyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiro","family":"Miura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihito","family":"Uchino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiromichi","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaru","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuhide","family":"Iizuka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Hamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Hatta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiro","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masami","family":"Takei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,7,24]]},"reference":[{"key":"1298_CR1","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","volume":"133","author":"C Pawlyn","year":"2019","unstructured":"Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133:660\u201375.","journal-title":"Blood"},{"key":"1298_CR2","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood-2014-10-567370","volume":"125","author":"J Corre","year":"2015","unstructured":"Corre J, Munshi N, Avet-Loiseau H. Genetics of multiple myeloma: another heterogeneity level? Blood. 2015;125:1870\u20136.","journal-title":"Blood"},{"key":"1298_CR3","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1182\/blood-2014-11-568881","volume":"125","author":"G Bianchi","year":"2015","unstructured":"Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125:3049\u201358.","journal-title":"Blood"},{"key":"1298_CR4","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","volume":"14","author":"S Manier","year":"2017","unstructured":"Manier S, Salem KZ, Park J, Landau DA, Getz G, Ghobrial IM. Genomic complexity of multiple myeloma and its clinical implications. Nat Rev Clin Oncol. 2017;14:100\u201313.","journal-title":"Nat Rev Clin Oncol"},{"key":"1298_CR5","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1038\/s41375-018-0153-6","volume":"32","author":"J Corre","year":"2018","unstructured":"Corre J, Cleynen A, Robiou du Pont S, Buisson L, Bolli N, et al. Multiple myeloma clonal evolution in homogeneously treated patients. Leukemia. 2018;32:2636\u201347.","journal-title":"Leukemia"},{"key":"1298_CR6","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","volume":"130","author":"P Moreau","year":"2017","unstructured":"Moreau P. How I treat myeloma with new agents. Blood. 2017;130:1507\u201313.","journal-title":"Blood"},{"key":"1298_CR7","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/leu.2017.329","volume":"32","author":"CS Chim","year":"2018","unstructured":"Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, et al. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond. Leukemia. 2018;32:252\u201362.","journal-title":"Leukemia"},{"key":"1298_CR8","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1182\/blood-2012-04-403733","volume":"120","author":"P Moreau","year":"2012","unstructured":"Moreau P, Richardson PG, Cavo M, Orlowski RZ, San Miguel JF, Palumbo A, Harousseau JL. Proteasome inhibitors in multiple myeloma: 10\u00a0years later. Blood. 2012;120:947\u201359.","journal-title":"Blood"},{"key":"1298_CR9","doi-asserted-by":"crossref","first-page":"62435","DOI":"10.18632\/oncotarget.18722","volume":"8","author":"J Liu","year":"2017","unstructured":"Liu J, Yang H, Liang X, Wang Y, Hou J, Liu Y, et al. Meta-analysis of the efficacy of treatments for newly diagnosed and relapsed\/refractory multiple myeloma with del(17p). Oncotarget. 2017;8:62435\u201344.","journal-title":"Oncotarget"},{"key":"1298_CR10","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","volume":"127","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, et al. Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. Blood. 2016;127:2955\u201362.","journal-title":"Blood"},{"key":"1298_CR11","doi-asserted-by":"publisher","first-page":"3412","DOI":"10.1200\/JCO.2005.04.242","volume":"23","author":"PR Greipp","year":"2005","unstructured":"Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blad\u00e9 J, et al. International Staging System for multiple myeloma. J Clin Oncol. 2005;23:3412\u201320.","journal-title":"J Clin Oncol"},{"key":"1298_CR12","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.1182\/blood.V81.10.2658.2658","volume":"81","author":"H Harada","year":"1993","unstructured":"Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81:2658\u201363.","journal-title":"Blood"},{"key":"1298_CR13","doi-asserted-by":"crossref","first-page":"3721","DOI":"10.1182\/blood.V82.12.3721.3721","volume":"82","author":"N Huang","year":"1993","unstructured":"Huang N, Kawano MM, Harada H, Harada Y, Sakai A, Kuramoto A, Niwa O. Heterogeneous expression of a novel MPC-1 antigen on myeloma cells: possible involvement of MPC-1 antigen in the adhesion of mature myeloma cells to bone marrow stromal cells. Blood. 1993;82:3721\u20139.","journal-title":"Blood"},{"key":"1298_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12032-016-0803-3","volume":"33","author":"N Iriyama","year":"2016","unstructured":"Iriyama N, Miura K, Hatta Y, Uchino Y, Kurita D, Takahashi H, et al. Plasma cell maturity as a predictor of prognosis in multiple myeloma. Med Oncol. 2016;33:87.","journal-title":"Med Oncol"},{"key":"1298_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1034\/j.1600-065X.2003.00040.x","volume":"194","author":"K-I Lin","year":"2003","unstructured":"Lin K-I, Tunyaplin C, Calame K. Transcriptional regulatory cascades controlling plasma cell differentiation. Immunol Rev. 2003;194:19\u201328.","journal-title":"Immunol Rev"},{"key":"1298_CR16","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1038\/ni907","volume":"4","author":"NN Iwakoshi","year":"2003","unstructured":"Iwakoshi NN, Lee A-H, Vallabhajosyula P, Otipoby KL, Rajewsky K, Glimcher LH. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nat Immunol. 2003;4:321\u20139.","journal-title":"Nat Immunol"},{"key":"1298_CR17","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1182\/blood-2010-01-263236","volume":"116","author":"T Bagratuni","year":"2010","unstructured":"Bagratuni T, Wu P, GonzalezdeCastro D, Davenport EL, Dickens NJ, Walker BA, et al. XBP1\u00a0s levels are implicated in the biology and outcome of myeloma mediating different clinical outcomes to thalidomide-based treatments. Blood. 2010;116:250\u20133.","journal-title":"Blood"},{"key":"1298_CR18","doi-asserted-by":"publisher","first-page":"3803","DOI":"10.3892\/ol.2017.5920","volume":"13","author":"N Iriyama","year":"2017","unstructured":"Iriyama N, Miura K, Hatta Y, Kobayashi S, Uchino Y, Kurita D, et al. Clinical effect of immunophenotyping on the prognosis of multiple myeloma patients treated with bortezomib. Oncol Lett. 2017;13:3803\u20138.","journal-title":"Oncol Lett"},{"key":"1298_CR19","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1038\/leu.2009.26","volume":"23","author":"CB Reeder","year":"2009","unstructured":"Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, et al. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23:1337\u201341.","journal-title":"Leukemia"},{"key":"1298_CR20","doi-asserted-by":"publisher","first-page":"906","DOI":"10.1056\/NEJMoa0801479","volume":"359","author":"JF San Miguel","year":"2008","unstructured":"San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, et al. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med. 2008;359:906\u201317.","journal-title":"N Engl J Med"},{"key":"1298_CR21","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1007\/s12185-016-2016-0","volume":"104","author":"M Ri","year":"2016","unstructured":"Ri M. Endoplasmic-reticulum stress pathway-associated mechanisms of action of proteasome inhibitors in multiple myeloma. Int J Hematol. 2016;104:273\u201380.","journal-title":"Int J Hematol"},{"key":"1298_CR22","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccr.2013.08.009","volume":"24","author":"C Leung-Hagesteijn","year":"2013","unstructured":"Leung-Hagesteijn C, Erdmann N, Cheung G, Keats JJ, Stewart AK, Reece DE, et al. Xbp1\u00a0s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2013;24:289\u2013304.","journal-title":"Cancer Cell"},{"key":"1298_CR23","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1532\/IJH97.04189","volume":"81","author":"Y Kuroda","year":"2005","unstructured":"Kuroda Y, Sakai A, Okikawa Y, Munemasa S, Katayama Y, Hyodo H, et al. The maturation of myeloma cells correlates with sensitivity to chemotherapeutic agents. Int J Hematol. 2005;81:335\u201341.","journal-title":"Int J Hematol"},{"key":"1298_CR24","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621\u201331.","journal-title":"N Engl J Med"},{"key":"1298_CR25","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319\u201331.","journal-title":"N Engl J Med"},{"key":"1298_CR26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1182\/bloodadvances.2016002493","volume":"1","author":"LJ Costa","year":"2017","unstructured":"Costa LJ, Brill IK, Omel J, Godby K, Kumar SK, Brown EE. Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States. Blood Adv. 2017;1:282\u20137.","journal-title":"Blood Adv"},{"key":"1298_CR27","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.leukres.2016.03.003","volume":"44","author":"WI Gonsalves","year":"2016","unstructured":"Gonsalves WI, Timm MM, Rajkumar SV, Morice WG, Dispenzieri A, Buadi FK, et al. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leuk Res. 2016;44:32\u20139.","journal-title":"Leuk Res"},{"key":"1298_CR28","first-page":"547","volume":"89","author":"P Moreau","year":"2004","unstructured":"Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, et al. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica. 2004;89:547\u201351.","journal-title":"Haematologica"},{"key":"1298_CR29","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s12185-014-1539-5","volume":"99","author":"J Kuroda","year":"2014","unstructured":"Kuroda J, Shimura Y, Ohta K, Tanaka H, Shibayama H, Kosugi S, et al. Limited value of the International Staging System for predicting long-term outcome of transplant-ineligible, newly diagnosed, symptomatic multiple myeloma in the era of novel agents. Int J Hematol. 2014;99:441\u20139.","journal-title":"Int J Hematol"},{"key":"1298_CR30","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.leukres.2013.06.008","volume":"37","author":"D Tan","year":"2013","unstructured":"Tan D, Kim K, Kim JS, Eom HS, Teoh G, Ong KH, et al. The impact of upfront versus sequential use of bortezomib among patients with newly diagnosed multiple myeloma (MM): a joint analysis of the Singapore MM Study Group and the Korean MM Working Party for the Asian myeloma network. Leuk Res. 2013;37:1070\u20136.","journal-title":"Leuk Res"},{"key":"1298_CR31","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1002\/hon.2026","volume":"31","author":"D Maltezas","year":"2013","unstructured":"Maltezas D, Dimopoulos MA, Katodritou I, Repousis P, Pouli A, Terpos E, et al. Re-evaluation of prognostic markers including staging, serum free light chains or their ratio and serum lactate dehydrogenase in multiple myeloma patients receiving novel agents. Hematol Oncol. 2013;31:356\u201362.","journal-title":"Hematol Oncol"},{"key":"1298_CR32","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: a Report From International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-019-1298-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12032-019-1298-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-019-1298-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,22]],"date-time":"2020-07-22T23:17:31Z","timestamp":1595459851000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12032-019-1298-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,24]]},"references-count":32,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["1298"],"URL":"https:\/\/doi.org\/10.1007\/s12032-019-1298-5","relation":{},"ISSN":["1357-0560","1559-131X"],"issn-type":[{"value":"1357-0560","type":"print"},{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,24]]},"assertion":[{"value":"9 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"NI received honoraria and speaker fees from Bristol-Myers Squibb, Celgene K.K., Takeda Pharma Co., Ltd., and Ono Parma Co., Ltd. KM received honoraria and speaker fees from Celgene K.K., Takeda Pharma Co., Ltd., and Ono Parma Co., Ltd. HT, MN, and TH reports honoraria and speaker fees from Bristol-Myers Squibb. YH received speaker fees and honoraria from Celgene K.K., Janssen Pharmaceutical K.K., Bristol-Myers Squibb, Takeda Pharma Co., Ltd., and Ono Parma Co., Ltd. MT received honoraria from Janssen Pharmaceutical K.K., Bristol-Myers Squibb, Takeda Pharma Co., Ltd., and Ono Parma Co., Ltd., supports for extension lectures from Bristol-Myers Squibb, and scholarship funds from Takeda Pharma Co., Ltd. and Ono Parma Co., Ltd. In addition, MT is part of an international clinical trial evaluating an investigational drug that was developed by Bristol-Myers Squibb for the treatment of Sj\u00f6gren\u2019s syndrome and has cooperative research with Celgene K.K. The remaining co-authors declare no competing financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures were performed in accordance with the ethical standards of the Institutional Research Committee of the Nihon University Itabashi Hospital and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was not required due to retrospective nature of this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"75"}}